Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study
Open Access
- 29 October 2019
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 1-15
Abstract
Background: The only licensed malaria vaccine, RTS,S/AS01, has been developed for morbidity-control in young children. The potential impact on transmission of deploying such anti-infective vaccines to wider age ranges, possibly with co-administration of antimalarial treatment, is unknown. Combinations of existing malaria interventions is becoming increasingly important as evidence mounts that progress on reducing malaria incidence is stalling and threatened by resistance. Methods: Malaria transmission and intervention dynamics were simulated using OpenMalaria, an individual-based simulation model of malaria transmission, by considering a seasonal transmission setting and by varying epidemiological and setting parameters such as transmission intensity, case management, intervention types and intervention coverages. Chemopreventive drugs and anti-infective vaccine efficacy profiles were based on previous studies in which model parameters were fitted to clinical trial data. These intervention properties were used to evaluate the potential of seasonal mass applications of preventative anti-infective malaria vaccines, alone or in combination with chemoprevention, to reduce malaria transmission, prevent resurgence, and/or reach transmission interruption. Results: Deploying a vaccine to all ages on its own is a less effective intervention strategy compared to chemoprevention alone. However, vaccines combined with drugs are likely to achieve dramatic prevalence reductions and in few settings, transmission interruption. The combined mass intervention will result in lower prevalence following the intervention compared to chemoprevention alone and will increase chances of interruption of transmission resulting from a synergistic effect between both interventions. The combination of vaccine and drug increases the time before transmission resurges after mass interventions cease compared to mass treatment alone. Deploying vaccines and drugs together requires fewer rounds of mass intervention and fewer years of intervention to achieve the same public health impact as chemoprevention alone. Conclusions: Through simulations we identified a previously unidentified value of deploying vaccines with drugs, namely the greatest benefit will be in preventing and delaying transmission resurgence for longer periods than with other human targeted interventions. This is suggesting a potential role for deploying vaccines alongside drugs in transmission foci as part of surveillance-response strategies.Keywords
Funding Information
- Swiss National Science Foundation (PP00P3_170702)
This publication has 33 references indexed in Scilit:
- Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trialThe Lancet, 2015
- Effective Coverage and Systems Effectiveness for Malaria Case Management in Sub-Saharan African CountriesPLOS ONE, 2015
- Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malariaCochrane Database of Systematic Reviews, 2014
- Mass drug administration for malariaCochrane Database of Systematic Reviews, 2013
- Ensemble Modeling of the Likely Public Health Impact of a Pre-Erythrocytic Malaria VaccinePLOS Medicine, 2012
- A Periodically-Forced Mathematical Model for the Seasonal Dynamics of Malaria in MosquitoesBulletin of Mathematical Biology, 2012
- Estimating the potential public health impact of seasonal malaria chemoprevention in African childrenNature Communications, 2012
- Notions of synergy for combinations of interventions against infectious diseases in heterogeneously mixing populationsMathematical Biosciences, 2010
- Control to elimination: implications for malaria researchTrends in Parasitology, 2008
- What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria VaccinesPLOS ONE, 2008